Table 1. Disease severity and serum hBD-2 of patients and controls.
| Diagnosis | Disease severity | Disease score | N | Serum hBD-2 (ng/ml) |
| Controls | n.a. | n.a. | 70 | 0.21±0.17 |
| Psoriasis | remission, PASI 0–1 | 0.4±0.4 | 3 | 0.64±0.36 |
| low, PASI 1–10 | 6.0±2.7 | 18 | 4.5±4.6 | |
| moderate, PASI 10–20 | 15.1±2.8 | 12 | 11.5±9.1 | |
| high, PASI>20 | 30.2±3.6 | 5 | 84.2±80.0 | |
| Atopic dermatitis | remission, SCORAD 0–5 | 0±0 | 2 | 0.10±0.01 |
| low, SCORAD 5–15 | 12.0±2.8 | 2 | 0.12±0.03 | |
| moderate, SCORAD 15–40 | 27.9±9.4 | 6 | 1.05±0.95 | |
| high, SCORAD>40 | 47.6±5.0 | 2 | 1.39±0.74 | |
| Rheumatoid arthritis | remission, DAS28 0–2.6 | 2.1±0.5 | 10 | 0.33±0.16 |
| low DAS28, 2.6–3.2 | 2.9±0.1 | 5 | 0.34±0.19 | |
| moderate, DAS28 3.2–5.1 | 4.2±0.6 | 16 | 0.51±0.41 | |
| high, DAS28>5.1 | 6.0±0.4 | 9 | 0.83±0.59 |
Serum hBD-2 levels were determined by ELISA. Analysis of variance on log transformed data showed that there was a significant correlation between disease severity and serum hBD-2 levels in psoriasis patients (p<2×10−5). Disease scores and serum hBD-2 concentration are given as mean and SD. n.a. not applicable.